Plus Therapeutics (PSTV) Research & Development (2011 - 2026)

Plus Therapeutics (PSTV) has 16 years of Research & Development data on file, last reported at $2.9 million in Q1 2026.

• Research & Development for Q1 2026 came in at $2.9 million, up 63.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.5 million (down 0.89% YoY), and the FY2025 annual result was $8.4 million, down 20.8% from the prior year.
• Research & Development declined to $2.9 million in Q1 2026 per PSTV's latest filing, from $2.9 million in the prior quarter.
• Over five years, Research & Development peaked at $3.0 million in Q1 2023 and troughed at $75000.0 in Q4 2023.
• A 5-year average of $2.3 million and a median of $2.5 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2023 and 2024: Research & Development plunged 96.49% in 2023, then surged 2814.67% in 2024.
• A 5-year view of Research & Development shows it stood at $2.1 million in 2022, then sank by 96.49% to $75000.0 in 2023, then surged by 2814.67% to $2.2 million in 2024, then soared by 34.54% to $2.9 million in 2025, then dropped by 2.58% to $2.9 million in 2026.
• Business Quant data shows PSTV's Research & Development at $2.9 million in Q1 2026, $2.9 million in Q4 2025, and $2.4 million in Q3 2025.